Tom Beer

About Tom Beer

Medical leader of the Abbott Cancer Diagnostics team that launched the multi-cancer early detection Cancerguard® test. Principal Investigator of the PREVAIL trial that established enzalutamide as a global standard of care in chemotherapy-naive metastatic castration-resistant prostate cancer. Formerly, the founding Chief Medical Office of the Center or Early Detection Advanced Research and Deputy Cancer Center Director at the Knight Cancer Institute. Medical Oncologist for men with prostate cancer.

Experience

1. Vice President and Chief Medical Officer for Multi-cancer Early Detection

   Exact Sciences

   Aug 2022 — Present

   Medical leader of the team that launched the Cancerguard® test, a multi-cancer early detection (MCED) test that extends cancer screening to many of the 70% of cancers not screened for today. Medical leader for the endometrial cancer program.

Education

• Oregon Health & Science University

  Fellow, Hematology and Medical Oncology

• Johns Hopkins School of Advanced International Studies (SAIS)

  Graduate Studies, International Relations and Affairs

  1988 — 1988

• Oregon Health & Science University

  Chief Resident, Internal Medicine Residency Program

• The Johns Hopkins University

  BA, Biomedical Engineering

  1983 — 1986

• The Johns Hopkins University School of Medicine

  M.D., Medicine

  1986 — 1991

• Oregon Health & Science University

  Resident, Internal Medicine Residency Program

• Harvard T.H. Chan School of Public Health

  Leadership Development for Physicians in Academic Health Centers